SÜTCÜOĞLU, O. Et Al. 2021. Re: Post-progression outcomes of NSCLC patients with PD-L1 expression >= 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. EUROPEAN JOURNAL OF CANCER , vol.155 , 294-295.

SÜTCÜOĞLU, O., ÖZDEMİR, N., & YAZICI, O., (2021). Re: Post-progression outcomes of NSCLC patients with PD-L1 expression >= 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. EUROPEAN JOURNAL OF CANCER , vol.155, 294-295.

SÜTCÜOĞLU, OSMAN, NURİYE ÖZDEMİR, And OZAN YAZICI. "Re: Post-progression outcomes of NSCLC patients with PD-L1 expression >= 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study," EUROPEAN JOURNAL OF CANCER , vol.155, 294-295, 2021

SÜTCÜOĞLU, OSMAN Et Al. "Re: Post-progression outcomes of NSCLC patients with PD-L1 expression >= 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study." EUROPEAN JOURNAL OF CANCER , vol.155, pp.294-295, 2021

SÜTCÜOĞLU, O. ÖZDEMİR, N. And YAZICI, O. (2021) . "Re: Post-progression outcomes of NSCLC patients with PD-L1 expression >= 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study." EUROPEAN JOURNAL OF CANCER , vol.155, pp.294-295.

@article{article, author={OSMAN SÜTCÜOĞLU Et Al. }, title={Re: Post-progression outcomes of NSCLC patients with PD-L1 expression >= 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study}, journal={EUROPEAN JOURNAL OF CANCER}, year=2021, pages={294-295} }